Drug intelligence / Profile preview

BWC6323

Development stage: Preclinical
Lead developer: Bugworks Research
Modality: Small Molecules
Administration: Oral

Overview

BWC6323 is a preclinical-stage small molecule dual inhibitor of cyclin-dependent kinase 7 (CDK7) and cyclin-dependent kinase 9 (CDK9), developed by Bugworks Research. It is designed to target cancers that exhibit transcriptional dependency, particularly MYC-driven, MCL1-dependent, and transcriptionally addicted solid tumors. By inhibiting both CDK7 and CDK9, BWC6323 aims to disrupt oncogenic transcription and cell-cycle progression, offering a potential therapeutic approach for cancers resistant to conventional cell-cycle or targeted therapies.

Targets

CDK7CDK9 (Cyclin-dependent kinase 9)

Beyond the preview

Go deeper on BWC6323.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BWC6323.